INT101410

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2002
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 5
Total Number 5
Disease Relevance 0.23
Pain Relevance 1.96

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP2C9) oxidoreductase activity (CYP2C9) endoplasmic reticulum (CYP2C9)
Anatomy Link Frequency
hepatocytes 2
CYP2C9 (Homo sapiens)
Pain Link Frequency Relevance Heat
fluoxetine 14 99.84 Very High Very High Very High
sSRI 16 96.96 Very High Very High Very High
antidepressant 4 94.24 High High
Versed 1 83.96 Quite High
diclofenac 1 79.44 Quite High
antagonist 22 75.00 Quite High
headache 2 42.72 Quite Low
Bioavailability 2 31.60 Quite Low
depression 2 25.00 Low Low
dexamethasone 35 18.60 Low Low
Disease Link Frequency Relevance Heat
Disorders Of Creatine Metabolism 1 81.12 Quite High
Pulmonary Hypertension 5 77.56 Quite High
Vomiting 117 50.00 Quite Low
Headache 2 42.72 Quite Low
Increased Venous Pressure Under Development 1 41.92 Quite Low
Pressure And Volume Under Development 1 38.32 Quite Low
Anaemia 2 37.12 Quite Low
Dizziness 1 11.76 Low Low
Neutropenia 8 5.00 Very Low Very Low Very Low
Post-operative Nausea 6 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
A very weak time-dependent CYP2C9 inhibitor (AZ1, a proprietary AstraZeneca compound; KI 30 microM and kinact 0.02 min(-1)) effectively abolished CYP2C9 activity over 24 h at low (micromolar) concentrations in primary cultured human hepatocytes.
Negative_regulation (abolished) of Positive_regulation (time-dependent) of CYP2C9 in hepatocytes
1) Confidence 0.42 Published 2006 Journal Drug Metab. Dispos. Section Abstract Doc Link 16679385 Disease Relevance 0 Pain Relevance 0.41
Fluvoxamine is a potent CYP1A2 and CYP2C19 inhibitor, and a moderate CYP2C9, CYP2D6, and CYP3A4 inhibitor.
Negative_regulation (inhibitor) of Positive_regulation (potent) of CYP2C9
2) Confidence 0.09 Published 2002 Journal Curr. Drug Metab. Section Abstract Doc Link 11876575 Disease Relevance 0 Pain Relevance 0.75
Fluvoxamine is a potent CYP1A2 and CYP2C19 inhibitor, and a moderate CYP2C9, CYP2D6, and CYP3A4 inhibitor.
Negative_regulation (inhibitor) of Positive_regulation (potent) of CYP2C9
3) Confidence 0.09 Published 2002 Journal Curr. Drug Metab. Section Abstract Doc Link 11876575 Disease Relevance 0 Pain Relevance 0.76
In vitro studies had shown that casopitant is a dose and durationdependent inhibitor of CYP3A4, and a moderate inducer of CYP2C9.
Negative_regulation (inhibitor) of Positive_regulation (inducer) of CYP2C9
4) Confidence 0.08 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697542 Disease Relevance 0 Pain Relevance 0
Bosentan decreases exposure to ciclosporin, glibenclamide, simvastatin (and beta-hydroxyacid simvastatin) and (R)- and (S)-warfarin by up to 50% because of induction of CYP3A4 and/or CYP2C9.
Negative_regulation (decreases) of Positive_regulation (induction) of CYP2C9
5) Confidence 0.06 Published 2004 Journal Clin Pharmacokinet Section Abstract Doc Link 15568889 Disease Relevance 0.23 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox